Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents.

RESPOND Study Group, The (2021). Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS, 35(6), pp. 869-882. Wolters Kluwer Health 10.1097/QAD.0000000000002811

[img] Text
Incidence_of_dyslipidemia_in_people_with_HIV_who.3.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (400kB)

OBJECTIVE

To compare the incidence of dyslipidemia in people with HIV receiving integrase inhibitors (INSTI) versus boosted protease inhibitors (PI/b) and nonnucleoside reverse transcriptase inhibitors (NNRTI) within RESPOND consortium of prospective cohorts.

METHODS

Participants were eligible if they were at least 18 years, without dyslipidemia and initiated or switched to a three-drug antiretroviral therapy (ART)-regimen consisting of either INSTI, NNRTI, or PI/b for the first time, between 1 January 2012 and 31 December 2018. Dyslipidemia was defined as random total cholesterol more than 240 mg/dl, HDL less than 35 mg/dl, triglyceride more than 200 mg/dl, or initiation of lipid-lowering therapy. Poisson regression was used to determine the adjusted incidence rate ratios. Follow-up was censored after 3 years or upon ART-regimen discontinuation or last lipid measurement or 31 December 2019, whichever occurred first.

RESULTS

Overall, 4577 people with HIV were eligible (INSTI = 66.9%, PI/b = 12.5%, and NNRTI = 20.6%), 1938 (42.3%) of whom were ART-naive. During 1.7 (interquartile range, 0.6-3.0) median years of follow-up, 1460 participants developed dyslipidemia [incidence rate: 191.6 per 1000 person-years, 95% confidence interval (CI) 182.0-201.7]. Participants taking INSTI had a lower incidence of dyslipidemia compared with those on PI/b (adjusted incidence rate ratio 0.71; CI 0.59-0.85), but higher rate compared with those on NNRTI (1.35; CI 1.15-1.58). Compared with dolutegravir, the incidence of dyslipidemia was higher with elvitegravir/cobicistat (1.20; CI 1.00-1.43) and raltegravir (1.24; CI 1.02-1.51), but lower with rilpivirine (0.77; CI 0.63-0.94).

CONCLUSION

In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared with dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1473-5571

Publisher:

Wolters Kluwer Health

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

22 Jun 2021 15:56

Last Modified:

25 Aug 2022 16:44

Publisher DOI:

10.1097/QAD.0000000000002811

PubMed ID:

33443370

Additional Information:

Prof. A. Rauch is Collaborator of Respond Study Group

BORIS DOI:

10.48350/156133

URI:

https://boris.unibe.ch/id/eprint/156133

Actions (login required)

Edit item Edit item
Provide Feedback